342 related articles for article (PubMed ID: 6373933)
1. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.
Fidler IJ; Schroit AJ
J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
Sone S; Fidler IJ
J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635
[TBL] [Abstract][Full Text] [Related]
3. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.
Fidler IJ; Barnes Z; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1982 Feb; 42(2):496-501. PubMed ID: 7055801
[TBL] [Abstract][Full Text] [Related]
4. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.
Phillips NC; Moras ML; Chedid L; Lefrancier P; Bernard JM
Cancer Res; 1985 Jan; 45(1):128-34. PubMed ID: 3838084
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages.
Saiki I; Fidler IJ
J Immunol; 1985 Jul; 135(1):684-8. PubMed ID: 3923117
[TBL] [Abstract][Full Text] [Related]
6. Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.
Fidler IJ; Raz A; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1980 Dec; 40(12):4460-6. PubMed ID: 7002293
[TBL] [Abstract][Full Text] [Related]
7. Potential value of liposomes containing muramyl dipeptide for augmenting the tumoricidal activity of human alveolar macrophages.
Sone S; Tachibana K; Shono M; Ogushi F; Tsubura E
J Biol Response Mod; 1984; 3(2):185-94. PubMed ID: 6726281
[TBL] [Abstract][Full Text] [Related]
8. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide.
Key ME; Talmadge JE; Fogler WE; Bucana C; Fidler IJ
J Natl Cancer Inst; 1982 Nov; 69(5):1198-98. PubMed ID: 6957661
[TBL] [Abstract][Full Text] [Related]
9. The activation of tumoricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome-encapsulated immunomodulators.
Fogler WE; Talmadge JE; Fidler IJ
J Reticuloendothel Soc; 1983 Mar; 33(3):165-74. PubMed ID: 6834360
[TBL] [Abstract][Full Text] [Related]
10. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
[TBL] [Abstract][Full Text] [Related]
11. Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide.
Sone S; Tsubura E
J Immunol; 1982 Sep; 129(3):1313-7. PubMed ID: 7108208
[TBL] [Abstract][Full Text] [Related]
12. In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide.
Daemen T; Veninga A; Roerdink FH; Scherphof GL
Cancer Res; 1986 Sep; 46(9):4330-5. PubMed ID: 3731091
[TBL] [Abstract][Full Text] [Related]
13. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes.
Poste G; Kirsh R; Fogler WE; Fidler IJ
Cancer Res; 1979 Mar; 39(3):881-92. PubMed ID: 427777
[TBL] [Abstract][Full Text] [Related]
14. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.
Sone S; Poste G; Fidler IJ
J Immunol; 1980 May; 124(5):2197-202. PubMed ID: 7365253
[TBL] [Abstract][Full Text] [Related]
15. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide.
Schroit AJ; Fidler IJ
Cancer Res; 1982 Jan; 42(1):161-7. PubMed ID: 7053846
[TBL] [Abstract][Full Text] [Related]
16. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody.
Watanabe Y; Uchida E; Higuchi M; Imai Y; Osawa T
J Biol Response Mod; 1987 Oct; 6(5):556-68. PubMed ID: 3316511
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative.
Phillips NC; Tsao MS
Cancer Res; 1989 Feb; 49(4):936-9. PubMed ID: 2912563
[TBL] [Abstract][Full Text] [Related]
18. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
Sone S; Mutsuura S; Ogawara M; Tsubura E
J Immunol; 1984 Apr; 132(4):2105-10. PubMed ID: 6699409
[TBL] [Abstract][Full Text] [Related]
19. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes.
Fidler IJ; Raz A; Fogler WE; Hoyer LC; Poste G
Cancer Res; 1981 Feb; 41(2):495-504. PubMed ID: 7004633
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes.
Fidler IJ; Fogler WE; Kleinerman ES; Saiki I
J Immunol; 1985 Dec; 135(6):4289-96. PubMed ID: 3934281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]